Andrew J Muir

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint IL28B in the era of direct-acting antivirals for hepatitis C
    Andrew J Muir
    Duke Clinical Research Institute, Division of Gastroenterology, Duke University School of Medicine, Durham, NC 27715, USA
    J Clin Gastroenterol 47:222-7. 2013
  2. doi request reprint Approach to the treatment-naïve patient with HCV genotype 1 infection
    Andrew J Muir
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Room 0311 Terrace Level 2400 Pratt Street, Durham, NC 27715, USA
    Infect Dis Clin North Am 26:893-901. 2012
  3. doi request reprint Surgical clearance for the patient with chronic liver disease
    Andrew J Muir
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Clin Liver Dis 16:421-33. 2012
  4. ncbi request reprint An examination of factors predicting prioritization for liver transplantation
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    Liver Transpl 8:957-61. 2002
  5. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
  6. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
  7. doi request reprint Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
  8. doi request reprint Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
  9. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010

Detail Information

Publications53

  1. doi request reprint IL28B in the era of direct-acting antivirals for hepatitis C
    Andrew J Muir
    Duke Clinical Research Institute, Division of Gastroenterology, Duke University School of Medicine, Durham, NC 27715, USA
    J Clin Gastroenterol 47:222-7. 2013
    ..IL28B also predicts the likelihood of shortened duration of treatment with the protease inhibitor combination. As hepatitis C treatment moves towards interferon-free regimens, the role of IL28B in these regimens is under investigation...
  2. doi request reprint Approach to the treatment-naïve patient with HCV genotype 1 infection
    Andrew J Muir
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Room 0311 Terrace Level 2400 Pratt Street, Durham, NC 27715, USA
    Infect Dis Clin North Am 26:893-901. 2012
    ..These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients...
  3. doi request reprint Surgical clearance for the patient with chronic liver disease
    Andrew J Muir
    Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Clin Liver Dis 16:421-33. 2012
    ..In patients with liver disease, elective surgeries should be delayed to allow complete evaluation of the severity of liver disease, including the role of transplantation in the event of hepatic decompensation postoperatively...
  4. ncbi request reprint An examination of factors predicting prioritization for liver transplantation
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    Liver Transpl 8:957-61. 2002
    ..In conclusion, these data show the wide range of practice patterns with the use of status 2A, and these findings suggest that certain patient groups might have received preference in the previous liver transplant allocation system...
  5. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  6. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
    ..004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of IL28B genotype...
  7. doi request reprint Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  8. doi request reprint Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  9. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  11. doi request reprint Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..Conclusion: Two ITPA variants were strongly associated with protection against treatment-related anemia in patients with genotype 2/3 HCV, but they did not decrease the need for RBV dose reduction or increase the rate of SVR...
  12. doi request reprint Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  13. pmc Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
    Hans L Tillmann
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27705, USA
    J Hepatol 55:1195-200. 2011
    ..Here we analyzed the association of steatosis with IL28B genotype in treatment naïve patients with CHC...
  14. doi request reprint Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC 27701, USA
    Hepatology 52:822-32. 2010
    ....
  15. pmc Disparities in liver transplantation before and after introduction of the MELD score
    Cynthia A Moylan
    Division of Gastroenterology, Duke University Medical Center, PO Box 3913, Durham, NC 27710, USA
    JAMA 300:2371-8. 2008
    ..Before MELD, black patients were more likely to die or become too sick to undergo liver transplantation compared with white patients. Little information exists regarding sex and access to liver transplantation...
  16. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  17. doi request reprint Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response
    Andrew J Muir
    Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 54:1538-46. 2011
    ..The overall relapse rate was 16% (13/83). Adverse events were similar to those in previous trials with telaprevir, with 9% of patients discontinuing due to an adverse event (most commonly rash and anemia)...
  18. doi request reprint ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
    Jacques Fellay
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 464:405-8. 2010
    ..Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV...
  19. doi request reprint Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  20. doi request reprint Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
    ....
  21. doi request reprint Telaprevir for the treatment of chronic hepatitis C infection
    Andrew J Muir
    Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Anti Infect Ther 9:1105-14. 2011
    ..Viral resistance can develop during treatment with telaprevir, and patients will need to be educated on their role in adherence to minimize the risk of resistance and improve their chances of cure of HCV infection...
  22. doi request reprint Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner
    Paul J Clark
    Duke Clinical Research Institute and Department of Gastroenterology, Duke University Medical Center, Durham, NC 27715, USA
    Hepatology 56:49-56. 2012
    ..2 mg/dL; P(adj) = 0.0015], 7DHC [Δ0.0075 mg/dL; P(adj) = 0.0026], lathosterol [Δ0.0430 mg/dL P(adj) = 0.0405]). In contrast, lanosterol was unchanged after SVR (P = 0.9515)...
  23. pmc Diagnosis and treatment of chronic hepatitis C infection
    Keyur Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27707, USA
    BMJ 332:1013-7. 2006
  24. ncbi request reprint Treatment of hepatitis C in special populations
    Meera Ramamurthy
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Liver Dis 10:851-65. 2006
    ..These groups generally were not included in the early large clinical trials of HCV treatment. This article reviews recent findings in these patients groups and examines future directions...
  25. doi request reprint Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response
    Ziad F Gellad
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA
    Value Health 15:876-86. 2012
    ..The cost-effectiveness of truncated therapy is not known...
  26. pmc An interrupted time series evaluation of a hepatitis C intervention for persons with HIV
    Rae Jean Proeschold-Bell
    Duke University Global Health Institute, Duke University Center for Health Policy, Duke University, Durham, NC, USA
    AIDS Behav 15:1721-31. 2011
    ..Other communities may consider adopting this intervention. Additional HCV interventions for PLWHA with HIV are needed...
  27. doi request reprint Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era
    Carla W Brady
    Veterans Affairs Medical Center, Durham, NC, USA
    Liver Transpl 14:228-34. 2008
    ..06, 1.86) emerged as a predictor of increased odds of de novo HCC. A significant proportion of patients listed for OLT develop de novo HCC. Identifying predictors of HCC in these patients may facilitate timely HCC screening and diagnosis...
  28. ncbi request reprint Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites
    Andrew J Muir
    Division of Gastroenterology, Duke University, Durham, NC, USA
    N Engl J Med 350:2265-71. 2004
    ..The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause...
  29. pmc Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection
    Brianna L Norton
    Duke University Medical Center, Durham, North Carolina 22710, USA
    AIDS Patient Care STDS 26:541-5. 2012
    ..This increase was not solely due to liver related events. Instead, comorbidities such as diabetes, renal disease, and psychiatric/substance abuse played a larger role in the health-care utilization in the HIV/HCV coinfected population...
  30. pmc Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection
    Josephine H Li
    Institute for Genome Sciences and Policy, Durham, NC 27708, USA
    Hepatology 51:1904-11. 2010
    ..06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype...
  31. doi request reprint Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C
    Ziad F Gellad
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Antivir Ther 17:1189-99. 2012
    ..Our goal for this review is to facilitate an understanding of the importance of cost-effectiveness analyses in guiding policy decisions about the use of newly approved drugs as well as future therapies for hepatitis C...
  32. doi request reprint Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals
    Alison B Jazwinski
    Division of Gastroenterology, Duke University Medical Center, 2400 Pratt Street, Terrace Level, Room 0311, Durham, NC 27710, USA
    Gastroenterol Clin North Am 40:481-94. 2011
    ..Although there remains work to be done in the field of HCV, these therapies will allow many more patients the opportunity to eradicate HCV infection...
  33. doi request reprint Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia
    Karen R Canlas
    Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC 27705, USA
    J Clin Gastroenterol 42:844-8. 2008
    ..We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia...
  34. doi request reprint The use of mind-body medicine and prayer among adult patients with chronic hepatitis C
    Jacqueline A Richmond
    Gastroenterology Hepatology Research Program, Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterol Nurs 33:210-6. 2010
    ..To provide patient-centered healthcare, health providers need to be aware of the alternative support strategies, including mind-body medicine, used by patients...
  35. doi request reprint Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center
    Janice H Jou
    Duke University Medical Center, Box 3913, Durham, NC 27710, USA
    Dig Dis Sci 55:3591-6. 2010
    ..We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, and rates of liver transplantation...
  36. doi request reprint Multiphase multi-detector row computed tomography in the setting of chronic liver disease and orthotopic liver transplantation: can a series be eliminated in order to reduce radiation dose?
    Frank E Luke
    From the Department of Radiology, Duke University Medical Center, Durham, NC Department of Radiology, Penn State University, Hershey, Pa Department of Radiology, Wake Forest Baptist Medical Center, Winston Salem, NC GMC General Diagnostic Radiology, Danville, PA DXP Imaging, Shively, KY and Departments of Biostatistics and Medicine, Duke University Medical Center, Durham, NC
    J Comput Assist Tomogr 37:408-14. 2013
    ..The objectives of this study were to explore utilization of multi-detector row computed tomography (MDCT) in screening for hepatocellular carcinoma (HCC) and to modify a liver CT protocol with a goal of dose reduction...
  37. ncbi request reprint Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis
    Michael A Heneghan
    Department of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    J Hepatol 45:584-91. 2006
    ..Our aims were to evaluate the role of TPMT genotyping and phenotyping and to examine 6-TG and 6-MMP metabolite levels in patients with AIH...
  38. ncbi request reprint A survey of current liver biopsy practice patterns
    Andrew J Muir
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 35:86-8. 2002
    ..To survey clinicians regarding current liver biopsy practice patterns...
  39. ncbi request reprint Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection
    Steven L Condron
    Division of Gastroenterology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Transplantation 80:145-8. 2005
    ..Recent studies from selected centers have suggested that older donor age is associated with worse outcomes after transplantation for HCV...
  40. ncbi request reprint De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant
    Michael A Heneghan
    Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Am J Transplant 3:634-8. 2003
    ..No viable tumor was identified in the explanted liver. This case establishes that long-term complications associated with PSC and biliary-enteric surgery such as CCA may become apparent in new grafts post-transplant...
  41. pmc An integrated alcohol abuse and medical treatment model for patients with hepatitis C
    Rae Jean Proeschold-Bell
    Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, 2812 Erwin Rd, 403, Durham, NC 27705, USA
    Dig Dis Sci 57:1083-91. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment...
  42. ncbi request reprint Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission
    Charles D Scales
    Division of Gastroenterology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    J Clin Gastroenterol 40:913-8. 2006
    ..The objective of our investigation was to examine the clinical utilization of digital rectal examination (DRE) and fecal occult blood testing (FOBT) at hospital admission...
  43. ncbi request reprint Treatment of hepatitis C in special populations
    Cynthia A Moylan
    Division of Gastroenterology and Duke Clinical Research Institute, Duke University Medical Center, Box 3913, Durham, NC 27710, USA
    Clin Liver Dis 9:567-77, v. 2005
    ..This article reviews recent findings from research in these patient groups and examines future directions and treatment trials...
  44. doi request reprint Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV
    Rae Jean Proeschold-Bell
    Duke University Global Health Institute and Duke University Center for Health Policy, Durham, NC 27708, USA
    South Med J 103:635-41. 2010
    ..Little is known about the HCV knowledge of PLWHA...
  45. pmc Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C
    Donald E Bailey
    Duke University School of Nursing, DUMC PO Box 3322, Durham, NC 27710, USA
    Psychosomatics 50:138-46. 2009
    ..Chronic hepatitis C (CHC) is the most common blood-borne infection in the United States, but little is known about illness uncertainty in these patients...
  46. ncbi request reprint A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection
    Andrew J Muir
    Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Gastroenterol 34:268-71. 2002
    ..To assess the number of chronic hepatitis C patients eligible for therapy...
  47. ncbi request reprint Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
    Andrew J Muir
    Hepatology 44:1400-3. 2006
  48. ncbi request reprint Acute HCV: the early bird catches the virus
    Andrew J Muir
    Gastroenterology 122:1176-7; discussion 1177-8. 2002
  49. ncbi request reprint Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?
    Keyur Patel
    Hepatology 38:21-4. 2003
  50. ncbi request reprint Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin
    Vijayan Balan
    Division of Transplantation Medicine, Mayo Clinic Hospital, 5777 E Mayo Boulevard, Phoenix, AZ 85054, USA
    Am J Gastroenterol 100:299-307. 2005
    ..The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia...
  51. ncbi request reprint HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis
    Carla W Brady
    Hepatology 42:496-7; author reply 497. 2005
  52. ncbi request reprint In the clinic. Hepatitis C
    Janice H Jou
    Ann Intern Med 148:ITC6-1-ITC6-16. 2008
  53. ncbi request reprint Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients
    Keyur Patel
    Hepatology 37:1222; author reply 1222-3. 2003